Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Precision BioSciences IncDTIL6.100.700.700.7424.44%14.21%53.40$8.93$333.402,051$7.22

Detail of Precision BioSciences Inc

 
CEO
Mr. Michael Amoroso
Employees
108
Industry
Biotechnology
Sector
Healthcare
Market cap
$53M

Company details

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Revenue
Revenue (Rev)
$75.10M
Precision BioSciences Inc
DTIL • XNGS • US
$7.22
+6.81 (1,682.72%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$1.18
Margin profit
11.48%
52 week low
$0.36
52 week high
$18.559999
50-day simple moving average
$0.00
200-day simple moving average
$8.93
Percent held by insiders
6.58%
Percent held by institutions
44.70%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
DTIL +1,682.72%
eps change
DTIL 0.00%